# Basal Ganglia Dopamine Availability and Immune Activation Interact and Relate to Anhedonia Severity among Youth with Depression

**Authors:** Iris Ka-Yi Chat, James W. Murrough, Scott Russo, Finnegan Calabro, Beatriz Luna, Kalyan Tripathy, Tina Gupta, Zachary Brodnick, Megan M. Julien, Neil P. Jones, Neal D. Ryan, Helmet T. Karim, Rebecca B. Price, Jihui Diaz, Erika E. Forbes

PMC · DOI: 10.21203/rs.3.rs-8442008/v1 · Research Square · 2026-02-12

## TL;DR

This study explores how dopamine levels and immune system activity together affect anhedonia in young people with depression.

## Contribution

It identifies specific neuroimmune interactions in the basal ganglia that relate to different types of anhedonia.

## Key findings

- Higher immune activation amplifies the link between low dopamine and greater anhedonia in youth with depression.
- Dopaminergic-immune interactions vary across basal ganglia regions, with strongest effects in the putamen.
- Immune activation is more strongly linked to anticipatory than consummatory anhedonia.

## Abstract

Anhedonia emerges in adolescence, has putative substrates in neural reward and dopamine systems, and is a hallmark of poor course in depression. Psychoneuroimmunology models suggest altered immune and reward systems may jointly underlie its development. When dopamine availability (rather than function) is considered, immune activation may be understood as a moderator amplifying how lower dopamine levels translate into motivational deficits. This cross-sectional study analyzed data from 55 youth with current depression (Mage=21.4 years; Female=75%). Plasma was assayed for relative quantification of 92 immune proteins, followed by dimensionality reduction via principal component (PC) analysis, forming five PC scores. Dopamine availability was indexed by basal ganglia tissue iron, quantified by MRI R2’, a measure detectable in youth. Anhedonia was assessed using the Snaith–Hamilton Pleasure Scale (SHAPS), thought to capture overall anhedonia, and Positive Valence Systems Scale (PVSS), which provides overall, anticipatory, and consummatory anhedonia scores. PC1 scores—whose loadings indicated broadly distributed immune protein elevations consistent with general immune activation—moderated the relationship between basal ganglia dopamine availability and anhedonia: At higher PC1 levels, lower dopamine availability was linked to greater overall anhedonia (as measured by SHAPS) and anticipatory anhedonia, but not to consummatory anhedonia. Lower PC2 scores were associated with greater PVSS overall and consummatory anhedonia. Analyses examining individual basal ganglia regions suggest potential differences in dopaminergic-immune interactions across these regions, with effects most consistently observed in the putamen. Findings highlight nuanced neuroimmune pathways underlying anhedonia components in youth and support inflammation-based models of depression emphasizing dopaminergic-immune interplay.

## Linked entities

- **Diseases:** depression (MONDO:0002050)

## Full-text entities

- **Genes:** DNER (delta/notch like EGF repeat containing) [NCBI Gene 92737] {aka UNQ26, bet}, TNFSF12 (TNF superfamily member 12) [NCBI Gene 8742] {aka APO3L, DR3LG, TNF12, TNLG4A, TWEAK}, CCL23 (C-C motif chemokine ligand 23) [NCBI Gene 6368] {aka CK-BETA-8, CKb8, Ckb-8, Ckb-8-1, MIP-3, MIP3}, CX3CL1 (C-X3-C motif chemokine ligand 1) [NCBI Gene 6376] {aka ABCD-3, C3Xkine, CXC3, CXC3C, NTN, NTT}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, AXIN1 (axin 1) [NCBI Gene 8312] {aka AXIN, CMDOH, PPP1R49}, SIRT2 (sirtuin 2) [NCBI Gene 22933] {aka SIR2, SIR2L, SIR2L2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, STAMBP (STAM binding protein) [NCBI Gene 10617] {aka AMSH, MICCAP}, ADA (adenosine deaminase) [NCBI Gene 100] {aka ADA1}, LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}, PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}, OSM (oncostatin M) [NCBI Gene 5008], AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, KRT6B (keratin 6B) [NCBI Gene 3854] {aka CK-6B, CK6B, K6B, KRTL1, PC2, PC4}, SULT1A1 (sulfotransferase family 1A member 1) [NCBI Gene 6817] {aka HAST1/HAST2, P-PST, P-PST 1, PST, ST1A1, ST1A3}, PLAU (plasminogen activator, urokinase) [NCBI Gene 5328] {aka ATF, BDPLT5, QPD, UPA, URK, u-PA}, PCSK5 (proprotein convertase subtilisin/kexin type 5) [NCBI Gene 5125] {aka PC5, PC6, PC6A, SPC6}
- **Diseases:** psychosis (MESH:D011618), infection (MESH:D007239), cardiovascular or neurological disorders (MESH:D002318), brain injury (MESH:D001930), PVS (MESH:D015619), bipolar disorder (MESH:D001714), Depression (MESH:D003866), DSM-5 (MESH:D008232), loss of consciousness (MESH:D014474), psychiatric (MESH:D001523), substance use disorder (MESH:D019966), Anhedonia (MESH:D059445), Inflammation (MESH:D007249), motivational deficits (MESH:D009461), SCID-5 (MESH:D020914)
- **Chemicals:** benzodiazepines (MESH:D001569), levodopa (MESH:D007980), PVSS (-), Dopamine (MESH:D004298), DA (MESH:C025953), infliximab (MESH:D000069285), iron (MESH:D007501)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** PC3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12919203/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12919203/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12919203/full.md

---
Source: https://tomesphere.com/paper/PMC12919203